We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Blood Test Diagnoses Herpes Simplex Virus Infection

By LabMedica International staff writers
Posted on 07 Nov 2012
Polymerase chain reaction (PCR) is now the test of choice for identifying central nervous system infection caused by herpes simplex virus (HSV).

A longitudinal review of HSV PCR testing at two pediatric academic medical centers in the USA determined the clinical features of children positive for serum HSV through PCR testing.

Scientists at the University of Texas Southwestern Medical Center (Dallas, TX, USA) in collaboration with others carried out a retrospective review of all patients who had a serum HSV PCR test at the participating institutions from 2005 to 2010. The study focused on children with one positive blood HSV PCR test and reviewed their charts for demographic, clinical, and other data. They defined a neonatal HSV infection as occurring before 42 days of age.

More than 700 patients received blood HSV PCR testing during the study period. Of those children, 294 were infants younger than 42 days old. A positive HSV PCR test was found in 45 patients (6.1%), 21 of whom were infants. Of these infants, approximately 25% were diagnosed with skin, eye, and mouth HSV disease; another 25% were diagnosed with central nervous system HSV disease; and approximately 50% had disseminated HSV disease. One third of the neonatal HSV patients in this study died. For two of those infants, the blood HSV PCR was the only positive HSV test. In another four children, the blood HSV PCR was the first test that was positive.

Among the 24 older children with positive blood HSV PCR tests, 50% were immunocompromised. Another 29% suffered from atopic dermatitis. Mucocutaneous lesions were much more common, occurring in 92% of these older children and 13% of the older children died. In four of the older children, the blood HSV PCR was the only positive test, and it was the first positive test in another seven of these children, all of whom had vesicular lesions that would have clinically suggested an HSV diagnosis. The authors concluded that HSV PCR testing on serum samples can be a useful adjunct in the diagnosis of HSV, especially among young infants who are much less likely than older children to have mucocutaneous lesions. The study was published in the August 2012 edition of the Journal of Pediatrics.

Related Links:
University of Texas Southwestern Medical Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Automated Clinical Chemistry Analyzer
Envoy 500+

Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more